Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Urinary Bladder Neoplasms × lirilumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Multiple Myeloma 2 Leukemia, Myeloid, Acute 2 Leukemia 2 Urinary Bladder Neoplasms 1 Recurrence 1 Myelodysplastic Syndromes 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Lymphoid 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, Biphenotypic, Acute 1 Hodgkin Disease 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Advanced Cancer 1

Interventions

Gemcitabine 136 Cisplatin 100 pembrolizumab 70 Paclitaxel 39 Docetaxel 38 Carboplatin 37 Nivolumab 36 Cystectomy 36 Mitomycin 34 durvalumab 30 atezolizumab 29 Radiotherapy 27 Magnetic Resonance Spectroscopy 26 BCG Vaccine 23 Specimen Handling 22 avelumab 21 Doxorubicin 20 Fluorouracil 18 Cystoscopy 18 enfortumab vedotin 16 Methotrexate 15 Vinblastine 14 Standard of Care 14 Filgrastim 13 vinflunine 12 Ipilimumab 12 5-aminolevulinic acid hexyl ester 12 tremelimumab 11 Transurethral Resection of Bladder 11 Sunitinib 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03532451 2024-09-19

PrE0807

PrECOG, LLC.

Phase 1 Completed

43 enrolled 15 charts

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡